Floatz logo

(2Z)-4-(3,4-DICHLORPHENYL)-2-(2-(4-METHYLPIPERAZIN-1-YL)BENZYLIDENE)THIOMORPHOLIN-3-ONE

Depressive Disorder, Major

PfizerSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Depressive Disorder, Major cohort.

Asset / SponsorPhaseRating
Amitriptyline
Janssen Research & Development, LLC
Phase 4BBB
Pregabalin
Janssen Research & Development, LLC
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
Seroquel®
Janssen Research & Development, LLC
Phase 4BBB
((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST
Janssen Research & Development, LLC
Phase 3BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →